Breadcrumb

Asset Publisher

null José Luis Blanco´s group

Description

Resistance to antiretrovirals, STI's and Papilomavirus in HIV patients

Our research group have been working in this field for the last  years focused in three topics of HIV research:

  1. Resistance to antiretrovirals (for the last 12 years)
  2. Sexually transmitted Infections (STI) (for the last 5 years)
  3. Human Papilomavirus (HPV) (for the last 3 years)

The resistance to antiretroviral drugs could be both a cause and consequence of virological failure and it is therefore, one of the main topics of HIV therapy. Although Human Papilomavirus (HPV) infection is in fact another STI, it is considerated as another different topic due to, its exceptional prevalence in HIV infected individuals (mainly MSM) and, its role in the development of anal cancer.

Resistance to antiretrovirals
Our group has been and is involved in several trials that assess the role of the resistance to antiretrovirals drugs in the antiretroviral therapy efficacy. Our main research has been focused on genotype-clinical associations in which the clinical significance of drug resistance mutations are correlated with the virological response to a subsequent antiretroviral treatment regimen while controlling for other variables that influence clinical response. We have been involved as well in other pillars of antiviral drug resistance knowledge as genotype-phenotype associations, in many narrow colaborations with other agencies and groups (i.e. RIS or Stanford HIV Drug Resistance Database).

Sexually Transmitted Diseases
Our group has been also involved in the epidemiology, prevention and management of STI’s since these events gained increasing importance a few years ago. Together with other clinical research groups ( AIDS Study Group/Spanish AIDS Plan) we have been involved in developing prevention and management guidelines on sexually transmitted infections in HIV-infected patients. We are collaborating with other public agencies (CESCAT) and research groups (Microbiology Department Hospital Vall d’Hebron) in the epidemiology and patterns of resistance of different STI’s.

Human Papilomavirus infection
Our group is one of the first in Spain involved in the epidemiology, prevention and management of anal cancer related with the HPV in HIV+ infected people.  Our team is working in some projects with other research groups: Institut Català d’Oncologia (ICO), HIVACAT and Hospital Vall d’Hebron.

Related Assets

Members

José Luis Blanco
Merçe Alsina
Jordi Bosch
Ana Gonzalez-Cordón
Carlos Muñoz

Related Assets

Related Assets

Publications

  • In vitro effects of the CCR5 inhibitor maraviroc on human T cell function 
    Arberas H, Guardo AC, Bargalló ME, Maleno MJ, Calvo M, Blanco JL, García F, Gatell JM, Plana M.  J Antimicrob Chemother. 2012 Nov 14. 
  • Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy 
    Betancor G, Garriga C, Puertas MC, Nevot M, Anta L, Blanco JL, Pérez-Elías MJ, de Mendoza C, Martínez MA, Martinez-Picado J, Menéndez-Arias L; for the Resistance Platform of the Spanish AIDS Research Network (ResRIS).  Retrovirology. 2012 Aug 13;9(1):68. 
  • HIV integrase inhibitors in ART-experienced patients 
    Blanco JL, Martinez-Picado J.  Curr Opin HIV AIDS. 2012 Sep;7(5):415-21. 
  • Rilpivirine Resistance Mutations in HIV Patients Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Therapies. 
    Anta L, Llibre JM, Poveda E, Blanco JL, Alvarez M, Pérez-Elías MJ, Aguilera A, Caballero E, Soriano V, de Mendoza C; on behalf of the Resistance Platform of the Spanish AIDS Research Network  AIDS. 2012 Aug 7. 
  • Standardized representation, visualization and searchable repository of antiretroviral treatment-change episodes 
    Rhee SY, Blanco JL, Liu TF, Pere I, Kaiser R, Zazzi M, Incardona F, Towner W, Gatell JM, De Luca A, Fessel WJ, Shafer RW.  AIDS Res Ther. 2012 May 3;9(1):13. doi: 10.1186/1742-6405-9-13. 
  • Low rate of sustained virological response in an outbreak of acute hepatitis C in HIV-infected patients 
    Laguno M, Martínez-Rebollar M, Perez I, Costa J, Larrousse M, Calvo M, Loncá M, Muñoz A, González-Cordón A, Blanco JL, Martínez E, Gatell JM, Mallolas J.  AIDS Res Hum Retroviruses. 2012 Oct;28(10):1294-300. Epub 2012 Apr 20. 
  • HIV-1 integrase inhibitor resistance and its clinical implications 
    Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW.  J Infect Dis. 2011 May 1;203(9):1204-14. doi: 10.1093/infdis/jir025. 
  • A new multidisciplinary home care telemedicine system to monitor stable chronic human immunodeficiency virus-infected patients: a randomized study 
    León A, Cáceres C, Fernández E, Chausa P, Martin M, Codina C, Rousaud A, Blanch J, Mallolas J, Martinez E, Blanco JL, Laguno M, Larrousse M, Milinkovic A, Zamora L, Canal N, Miró JM, Gatell JM, Gómez EJ, García F.  PLoS One. 2011 Jan 21;6(1):e14515. doi: 10.1371/journal.pone.0014515. 
  • Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy 
    Poveda E, Anta L, Blanco JL, Casado JL, Gutiérrez F, García F, Gómez-Sirvent JL, Iribarren JA, Soriano V, de Mendoza C; Resistance Platform of the Spanish AIDS Research Network (ResRIS)  Antimicrob Agents Chemother. 2010 Jul;54(7):3018-20. doi: 10.1128/AAC.00160-10. 

Related Assets